-
EP2099823
European procedure
Extract from the Register of European Patents
EP About this file: EP2099823
| EP2099823 - VARIANT TARGET BINDING AGENTS AND USES THEREOF [Right-click to bookmark this link] | Status | Patent maintained as amended Status updated on 07.01.2022 Database last updated on 10.12.2024 | Most recent event Tooltip | 07.01.2022 | Patent maintained (B2 publication) | published on 09.02.2022 [2022/06] | Applicant(s) | For all designated states Seagen Inc. 21823 30th Drive S.E. Bothell, WA 98021 / US | [N/P] |
| Former [2021/01] | For all designated states Seagen Inc. 21823 30th Drive, S.E. Bothell, WA 98021 / US | ||
| Former [2009/38] | For all designated states Seattle Genetics, Inc. 21823 30th Drive, S.E. Bothell, WA 98021 / US | Inventor(s) | 01 /
MCDONAGH, Charlotte 21823 30th Drive SE Bothell, WA 98021 / US | 02 /
CARTER, Paul 21823 30th Drive South East Bothell, WA 98021 / US | 03 /
SUSSMAN, Django 21823 30th Drive SE Bothell, WA 98021 / US | [2009/38] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2022/06] |
| Former [2014/38] | Roques, Sarah Elizabeth J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
| Former [2009/38] | Roques, Sarah Elizabeth J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 07868966.8 | 01.12.2007 | [2009/38] | WO2007US86205 | Priority number, date | US20060872239P | 01.12.2006 Original published format: US 872239 P | US20070918563P | 16.03.2007 Original published format: US 918563 P | [2009/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2008070593 | Date: | 12.06.2008 | Language: | EN | [2008/24] | Type: | A2 Application without search report | No.: | EP2099823 | Date: | 16.09.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.06.2008 takes the place of the publication of the European patent application. | [2009/38] | Type: | B1 Patent specification | No.: | EP2099823 | Date: | 17.09.2014 | Language: | EN | [2014/38] | Type: | B2 New European patent specification | No.: | EP2099823 | Date: | 09.02.2022 | Language: | EN | [2022/06] | Search report(s) | International search report - published on: | US | 30.10.2008 | (Supplementary) European search report - dispatched on: | EP | 06.05.2010 | Classification | IPC: | A61K39/395, A61K47/48, A61K51/10, A61P35/00, C07K16/00, C07K16/28 | [2014/07] | CPC: |
A61K51/1027 (EP,US);
C07K16/30 (US);
A61K47/6811 (EP,US);
A61K47/6849 (EP,US);
A61K47/6861 (EP,US);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
C07K16/2875 (EP,US);
A61K2039/505 (US);
C07K2317/24 (EP,US);
C07K2317/41 (EP,US);
C07K2317/52 (EP,US);
C07K2317/53 (EP,US);
C07K2317/56 (EP,US);
C07K2317/565 (EP,US);
C07K2317/71 (EP,US);
C07K2317/732 (EP,US);
|
| Former IPC [2010/22] | A61K39/395, A61K47/48, A61P35/00, C07K16/00, C07K16/28, C12P21/08 | ||
| Former IPC [2009/38] | C07K16/00, C12P21/08, A61K39/395 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2022/06] |
| Former [2009/38] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | VERSCHIEDENE ZIELMOLEKÜLE BINDENDE MITTEL UND IHRE VERWENDUNG | [2009/38] | English: | VARIANT TARGET BINDING AGENTS AND USES THEREOF | [2009/38] | French: | AGENTS SE LIANTÀ DES CIBLES VARIABLES ET UTILISATIONS DE CEUX-CI | [2009/38] | Entry into regional phase | 26.06.2009 | National basic fee paid | 26.06.2009 | Search fee paid | 26.06.2009 | Designation fee(s) paid | 26.06.2009 | Examination fee paid | Examination procedure | 26.06.2009 | Examination requested [2009/38] | 26.11.2010 | Amendment by applicant (claims and/or description) | 10.01.2011 | Despatch of a communication from the examining division (Time limit: M04) | 24.03.2011 | Reply to a communication from the examining division | 15.04.2011 | Despatch of a communication from the examining division (Time limit: M04) | 15.06.2011 | Reply to a communication from the examining division | 28.06.2011 | Despatch of a communication from the examining division (Time limit: M04) | 28.10.2011 | Reply to a communication from the examining division | 15.11.2011 | Despatch of a communication from the examining division (Time limit: M02) | 24.01.2012 | Reply to a communication from the examining division | 17.07.2012 | Despatch of a communication from the examining division (Time limit: M04) | 19.11.2012 | Reply to a communication from the examining division | 02.07.2013 | Cancellation of oral proceeding that was planned for 04.07.2013 | 04.07.2013 | Date of oral proceedings (cancelled) | 18.02.2014 | Communication of intention to grant the patent | 12.05.2014 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 10.07.2014 | Communication of intention to grant the patent | 05.08.2014 | Fee for grant paid | 05.08.2014 | Fee for publishing/printing paid | 05.08.2014 | Receipt of the translation of the claim(s) | Divisional application(s) | EP13150865.7 / EP2609932 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.01.2011 | Opposition(s) | Opponent(s) | 01
16.06.2015
ADMISSIBLE EIP Limited Fairfax House 15 Fulwood Place London WC1V 6HU / GB Opponent's representative EIP, et al, et al Fairfax House 15 Fulwood Place London WC1V 6HU / GB | [N/P] |
| Former [2015/30] | |||
| Opponent(s) | 01
16.06.2015
ADMISSIBLE EIP Limited Fairfax House 15 Fulwood Place London WC1V 6HU / GB Opponent's representative EIP, et al, et al Fairfax House 15 Fulwood Place London WC1V 6HU / GB | 22.07.2015 | Invitation to proprietor to file observations on the notice of opposition | 01.02.2016 | Reply of patent proprietor to notice(s) of opposition | 21.03.2017 | Date of oral proceedings | 13.04.2017 | Despatch of interlocutory decision in opposition | 13.04.2017 | Despatch of minutes of oral proceedings | 27.07.2021 | Legal effect of interlocutory decision in opposition | 30.09.2021 | Despatch of communication that the patent will be maintained as amended | 23.12.2021 | Fee for printing new specification paid | Appeal following opposition | 23.06.2017 | Appeal received No. T1433/17 | 23.08.2017 | Statement of grounds filed | 27.07.2021 | Result of appeal procedure: appeal of the opponent withdrawn | 27.07.2021 | Date of oral proceedings | Fees paid | Renewal fee | 28.12.2009 | Renewal fee patent year 03 | 27.12.2010 | Renewal fee patent year 04 | 27.12.2011 | Renewal fee patent year 05 | 26.12.2012 | Renewal fee patent year 06 | 27.12.2013 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | IT | 01.12.2014 | [2016/03] |
| Former [2015/18] | deleted | ||
| Former [2015/12] | LV | 17.09.2014 | Documents cited: | Search | [XI]WO2004042017 (GENENTECH INC [US], et al) [X] 1,15 * page 44, line 14 - page 47, line 16 * [I] 2-14; | [I]WO2005018572 (BIOGEN IDEC INC [US], et al) [I] 1-15 * page 12, line 9 - page 23, line 5; examples 1-3 *; | [A]WO2006034488 (GENENTECH INC [US], et al) [A] 1-15 * figures 16,17; examples 1-11 *; | [I]WO2006074397 (BIOGEN IDEC INC [US], et al) [I] 1-15 * page 7, line 21 - page 8, line 19 *; | [A]WO2006113909 (SEATTLE GENETICS INC [US], et al) [A] 1-15* the whole document * | International search | [X]US5624821 (WINTER GREGORY P [GB], et al); | [X]US6737056 (PRESTA LEONARD [US]); | [Y]US2006083736 (LAW CHE-LEUNG [US], et al) | Opposition | - CHARI et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs", Cancer Research, (19920101), vol. 52, pages 127 - 131 | - DORONINA et al., "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity", Bioconjugate Chem., (20060000), vol. 17, pages 114 - 124 |